DFTX (Definium Therapeutics) Interest Expense: $-6.13 Mil (TTM As of Mar. 2026)

What is Definium Therapeutics Interest Expense?

Definium Therapeutics DFTX +1.07% 32 Interest Expense is $-6.13 Mil as of Mar. 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Definium Therapeutics's interest expense for the three months ended in Mar. 2026 was $ -1.25 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.13 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Definium Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -59.22 Mil. Definium Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -1.25 Mil. Definium Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Definium Therapeutics (NAS:DFTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Definium Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $-1.25 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-59.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $40.77 Mil.

Definium Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Definium Therapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Definium Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Definium Therapeutics's Interest Expense can be seen below:

Definium Therapeutics Interest Expense Chart

Definium Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.36

0.00

-0.92

-2.28

-5.48

Definium Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.60	-2.34	-1.27	-1.27	-1.25

32GF Score

Definium Therapeutics Inc DFTX

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Definium Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.13 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-6.13 Mil mean?

Definium Therapeutics (DFTX) has a Interest Expense of $-6.13 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Definium Therapeutics and its competitors.

Is Definium Therapeutics' Interest Expense too high?

Definium Therapeutics' current Interest Expense is $-6.13 Mil. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Definium Therapeutics' Interest Expense compare to LGND and XENE?

Definium Therapeutics' Interest Expense of $-6.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Definium Therapeutics and its competitors. Definium Therapeutics's current Interest Expense is $-6.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Definium Therapeutics stock overvalued right now?

Definium Therapeutics (DFTX) has a current Interest Expense of $-6.13 Mil. The current Interest Expense is $-6.13 Mil. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current Interest Expense is $-6.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Definium Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies LGND XENE CGON LEGN TVTX ORKA COGT CRSP SRRK MANE VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges MMQ0:Germany

Address One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website https://www.definiumtx.com

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

32GF Score

Get the complete analysis for DFTX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$47.04

Price

View DFTX Analysis

See Interest Expense data for all stocks →